About
Science
- PAM Pathway
- Publications
Pipeline
Clinical Trials
Investors
Careers

Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models differing in PI3K or PTEN mutational status

Post navigation

A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)

A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)

Search for:

Recent Posts

Developing first-in-class therapeutics using a 3rd generation diagnostic platform

Recent Comments

Archives

October 2021

Categories

Uncategorized

Meta

Log in
Entries feed
Comments feed
WordPress.org

16305 36th Avenue North
Minneapolis, MN 55446

Follow us on

in x

©2025 Celcuity Inc.

Privacy Policy Accessibility Statement